Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Drugs and Companies Pipeline Review H2 2016

Friday, October 14, 2016 3:03
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H2 2016’, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/685900-radiation-toxicity-radiation-sickness-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) 
- The report reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics and enlists all their major and minor projects 
- The report assesses Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/685900-radiation-toxicity-radiation-sickness-review-h2-2016

 

Key points in table of content

Table of Contents 2 
List of Tables 6 
List of Figures 7 
Introduction 8 
Global Markets Direct Report Coverage 8 
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview 9 
Therapeutics Development 10 
Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Overview 10 
Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Comparative Analysis 11 
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Therapeutics under Development by Companies 12 
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Therapeutics under Investigation by Universities/Institutes 15 
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Products Glance 16 
Late Stage Products 16 
Clinical Stage Products 17 
Early Stage Products 18 
Unknown Stage Products 19 
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Products under Development by Companies 20 
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Products under Investigation by Universities/Institutes 24 
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Companies Involved in Therapeutics Development 25 
Aeolus Pharmaceuticals, Inc. 25 
Angion Biomedica Corp. 26 
Atox Bio Ltd. 27 
BCN Biosciences L.L.C. 28 
Bolder Biotechnology, Inc. 29 
Cellerant Therapeutics, Inc. 30 
Cellphire, Inc. 31 
Chrysalis BioTherapeutics, Inc. 32 
Cleveland BioLabs, Inc. 33 
Cumberland Pharmaceuticals, Inc. 34 
Diffusion Pharmaceuticals Inc. 35 
GNI Group Ltd. 36 
Humanetics Corporation 37 
INSYS Therapeutics, Inc. 38 
Meabco A/S 39 
Neumedicines Inc. 40 
Nohla Therapeutics Inc. 41 
Onconova Therapeutics, Inc. 42 
Original BioMedicals Co. Ltd. 43 
PharmaIN Corporation 44 
Pluristem Therapeutics Inc. 45 
RDD Pharma Ltd. 46 
Reata Pharmaceuticals, Inc. 47 
RedHill Biopharma Ltd. 48 
RxBio, Inc. 49 
SK Chemicals Co., Ltd. 50 
Soligenix, Inc. 51 
Stemedica Cell Technologies, Inc. 52 
Terapio Corporation 53 
Tonix Pharmaceuticals Holding Corp. 54 
Vida Therapeutics Inc. 55 
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Therapeutics Assessment 56 
Assessment by Monotherapy Products 56 
Assessment by Target 57 
Assessment by Mechanism of Action 60 
Assessment by Route of Administration 63 
Assessment by Molecule Type 65 
Drug Profiles 67 
A-02 – Drug Profile 67 
AB-103 – Drug Profile 68 
ABC-294640 – Drug Profile 71 
AEOL-10150 – Drug Profile 76 
AEOL-10171 – Drug Profile 85 
amifostine – Drug Profile 86 
Antisense RNAi Oligonucleotide for Influenza, Rheumatoid Arthritis and Radiation-Induced Fibrosis – Drug Profile 87 
AVMOC-001 – Drug Profile 88 
BB-3 – Drug Profile 89 
BBT-007 – Drug Profile 92 
BBT-015 – Drug Profile 93 
BBT-018 – Drug Profile 94 
BBT-059 – Drug Profile 95 
BCN-057 – Drug Profile 96 
BIO-300 – Drug Profile 97 
BMX-001 – Drug Profile 100 
BPC-2 – Drug Profile 101 
C-2E2 – Drug Profile 102 
C-2E5 – Drug Profile 103 
Cell Therapy for Acute Radiation Syndrome – Drug Profile 104 
cerium oxide – Drug Profile 105 
CLT-009 – Drug Profile 106 
Des-Asp Angiotensin 1 – Drug Profile 107 
Drug to Antagonize Adenosine A2A Receptor for Radiation Dermatitis – Drug Profile 108 
entolimod – Drug Profile 109 
EWA-001 – Drug Profile 116 
HSJ-0017 – Drug Profile 117 
JP4-039 – Drug Profile 118 
LGM-2605 – Drug Profile 120 
m-2A2 – Drug Profile 121 
molgramostim – Drug Profile 122 
monosodium luminol – Drug Profile 123 
NMIL-121 – Drug Profile 125 
omaveloxolone – Drug Profile 128 
ondansetron hydrochloride – Drug Profile 131 
ondansetron hydrochloride CR – Drug Profile 132 
Peptide to Agonize GHSR-1a for Acute Ischemic Stroke, Acute Radiation Syndrome, and Sepsis – Drug Profile 137 
pirfenidone – Drug Profile 138 
PLXR-18 – Drug Profile 140 
RDD-2007 – Drug Profile 146 
recilisib sodium – Drug Profile 147 
Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity – Drug Profile 149 
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis – Drug Profile 150 
Recombinant Protein to Activate FGF-4 for Radiation Injury – Drug Profile 151 
Recombinant Protein to Activate FGF-7 for Radiation Injury – Drug Profile 152 
RES-529 – Drug Profile 153 
RP-239X – Drug Profile 157 
rusalatide acetate – Drug Profile 158 
Rx-100 – Drug Profile 161 
SGX-201 – Drug Profile 163 
SGX-202 – Drug Profile 164 
SKI-2162 – Drug Profile 167 
Small Molecule to Inhibit GSK-3 for Acute and Late Radiation Injury – Drug Profile 168 
Small Molecules for Radiation and Chemical Toxicity – Drug Profile 169 
Small Molecules for Radiation Toxicity – Drug Profile 170 
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology – Drug Profile 171 
ST-266 – Drug Profile 172 
ST-7 – Drug Profile 174 
Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology – Drug Profile 175 
SY-303A – Drug Profile 181 
SY-513 – Drug Profile 182 
SYGN-305 – Drug Profile 183 
SYGN-399 – Drug Profile 184 
Thrombosomes – Drug Profile 185 
TPO-7630 – Drug Profile 186 
TPO-7640 – Drug Profile 187 
VEDA-1209 – Drug Profile 188 
VTI-1000 Series – Drug Profile 189 
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects 190 
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Discontinued Products 195 
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Product Development Milestones 196 
Featured News & Press Releases 196 
Appendix 206 
Methodology 206 
Coverage 206 
Secondary Research 206 
Primary Research 206 
Expert Panel Validation 206 
Contact Us 206 
Disclaimer 207

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=685900

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.